MGAT5 alters the severity of multiple sclerosis

B. Brynedal, J. Wojcik, F. Esposito, V. Debailleul, J. Yaouanq, F. Martinelli-Boneschi, G. Edan, G. Comi, J. Hillert, H. Abderrahim

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Multiple Sclerosis (MS) is a genetically complex immune mediated, demyelinating disease of the central nervous system. To date no genetic variants have been unambiguously linked to disease severity. We have conducted a genome wide screen, using Affymetrix Genechip® 500K technology, for severity in 1040 MS patients. Two markers within MGAT5, a gene coding for a glycosylation enzyme, were found to be significantly associated with outcome in the screening as well as in an independent population (combined p-values: 2.8 × 10- 6 and 1.5 × 10- 7).

Original languageEnglish
Pages (from-to)120-124
Number of pages5
JournalJournal of Neuroimmunology
Volume220
Issue number1-2
DOIs
Publication statusPublished - 30 Mar 2010
Externally publishedYes

Fingerprint

Multiple Sclerosis
Demyelinating Diseases
Antigen-Antibody Complex
Glycosylation
Central Nervous System
Genome
Technology
Enzymes
Population
Genes

Keywords

  • Genetic association
  • MGAT5
  • MSSS
  • Multiple sclerosis
  • Severity

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Brynedal, B., Wojcik, J., Esposito, F., Debailleul, V., Yaouanq, J., Martinelli-Boneschi, F., ... Abderrahim, H. (2010). MGAT5 alters the severity of multiple sclerosis. Journal of Neuroimmunology, 220(1-2), 120-124. https://doi.org/10.1016/j.jneuroim.2010.01.003

MGAT5 alters the severity of multiple sclerosis. / Brynedal, B.; Wojcik, J.; Esposito, F.; Debailleul, V.; Yaouanq, J.; Martinelli-Boneschi, F.; Edan, G.; Comi, G.; Hillert, J.; Abderrahim, H.

In: Journal of Neuroimmunology, Vol. 220, No. 1-2, 30.03.2010, p. 120-124.

Research output: Contribution to journalArticle

Brynedal, B, Wojcik, J, Esposito, F, Debailleul, V, Yaouanq, J, Martinelli-Boneschi, F, Edan, G, Comi, G, Hillert, J & Abderrahim, H 2010, 'MGAT5 alters the severity of multiple sclerosis', Journal of Neuroimmunology, vol. 220, no. 1-2, pp. 120-124. https://doi.org/10.1016/j.jneuroim.2010.01.003
Brynedal B, Wojcik J, Esposito F, Debailleul V, Yaouanq J, Martinelli-Boneschi F et al. MGAT5 alters the severity of multiple sclerosis. Journal of Neuroimmunology. 2010 Mar 30;220(1-2):120-124. https://doi.org/10.1016/j.jneuroim.2010.01.003
Brynedal, B. ; Wojcik, J. ; Esposito, F. ; Debailleul, V. ; Yaouanq, J. ; Martinelli-Boneschi, F. ; Edan, G. ; Comi, G. ; Hillert, J. ; Abderrahim, H. / MGAT5 alters the severity of multiple sclerosis. In: Journal of Neuroimmunology. 2010 ; Vol. 220, No. 1-2. pp. 120-124.
@article{e62051af1fa14eb1b3ec47e4bfa55736,
title = "MGAT5 alters the severity of multiple sclerosis",
abstract = "Multiple Sclerosis (MS) is a genetically complex immune mediated, demyelinating disease of the central nervous system. To date no genetic variants have been unambiguously linked to disease severity. We have conducted a genome wide screen, using Affymetrix Genechip{\circledR} 500K technology, for severity in 1040 MS patients. Two markers within MGAT5, a gene coding for a glycosylation enzyme, were found to be significantly associated with outcome in the screening as well as in an independent population (combined p-values: 2.8 × 10- 6 and 1.5 × 10- 7).",
keywords = "Genetic association, MGAT5, MSSS, Multiple sclerosis, Severity",
author = "B. Brynedal and J. Wojcik and F. Esposito and V. Debailleul and J. Yaouanq and F. Martinelli-Boneschi and G. Edan and G. Comi and J. Hillert and H. Abderrahim",
year = "2010",
month = "3",
day = "30",
doi = "10.1016/j.jneuroim.2010.01.003",
language = "English",
volume = "220",
pages = "120--124",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - MGAT5 alters the severity of multiple sclerosis

AU - Brynedal, B.

AU - Wojcik, J.

AU - Esposito, F.

AU - Debailleul, V.

AU - Yaouanq, J.

AU - Martinelli-Boneschi, F.

AU - Edan, G.

AU - Comi, G.

AU - Hillert, J.

AU - Abderrahim, H.

PY - 2010/3/30

Y1 - 2010/3/30

N2 - Multiple Sclerosis (MS) is a genetically complex immune mediated, demyelinating disease of the central nervous system. To date no genetic variants have been unambiguously linked to disease severity. We have conducted a genome wide screen, using Affymetrix Genechip® 500K technology, for severity in 1040 MS patients. Two markers within MGAT5, a gene coding for a glycosylation enzyme, were found to be significantly associated with outcome in the screening as well as in an independent population (combined p-values: 2.8 × 10- 6 and 1.5 × 10- 7).

AB - Multiple Sclerosis (MS) is a genetically complex immune mediated, demyelinating disease of the central nervous system. To date no genetic variants have been unambiguously linked to disease severity. We have conducted a genome wide screen, using Affymetrix Genechip® 500K technology, for severity in 1040 MS patients. Two markers within MGAT5, a gene coding for a glycosylation enzyme, were found to be significantly associated with outcome in the screening as well as in an independent population (combined p-values: 2.8 × 10- 6 and 1.5 × 10- 7).

KW - Genetic association

KW - MGAT5

KW - MSSS

KW - Multiple sclerosis

KW - Severity

UR - http://www.scopus.com/inward/record.url?scp=77649189376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649189376&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2010.01.003

DO - 10.1016/j.jneuroim.2010.01.003

M3 - Article

VL - 220

SP - 120

EP - 124

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -